Description of Invention: A new immunovaccine directed against the Pfs25 antigen of Plasmodium falciparum offers to significantly enhance the development of an effective antimalarial vaccine. Previously, peptides derived from the sporozoite and asexual stage of the parasite have only been able to stimulate weak production of antibodies. This Pfs25 antigen, which is only expressed in the sexual reproductive stage of the parasite, stimulates strong antibody response; anti-Pfs25 antibodies have effectively blocked the transmission of infection in animal studies.
For Licensing Information Please Contact: Kevin Chang Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-5018 Fax: 301-402-0220